Objective: Meningioma-associated protein (MAC30) is overexpressed in several types of cancers, but its therapeutic implication in the patients has not been studied. We examined the relationship of MAC30 with clinicopathological and biological factors in rectal cancer patients with or without radiotherapy (RT). Methods: MAC30 was immunohistochemically examined in 75 distant and 91 adjacent normal mucosa specimens, 132 primary tumours and 39 lymph node metastases from rectal cancer patients participating in a clinical trial of preoperative RT. Results: In the RT group, MAC30 was or tended to be positively correlated with infiltrated growth pattern (p = 0.02), PRL (phosphatase of regenerating liver, p = 0.01) and Ki-67 expression (p = 0.06). MAC30 at the invasive margin of the metastasis was related to poor survival (p = 0.02) in the whole group of patients. MAC30 in primary tumours was not related to recurrence and survival in the non-RT or RT group. Conclusions: MAC30 expression in metastasis was an indicator for poor survival. After RT, MAC30 seemed to be more related to aggressive morphological and biological factors; however, we did not find direct evidence that MAC30 expression was related to the outcome of patients with or without RT.

Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ 1993;4:715–722.
Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, Davidson S, Xu H, Chen A, Yamanishi DT, Lindemann GW, Cain CA, Madlansacay MR, Hashima SM, Pham TL, Mahoney W, Schueler PA: Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res 1999;27:839–847.
Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, Buchler MW, Friess H: Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol 2004;19:1021–1031.
Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, Sun XF: Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol 2007;30:91–95.
Atalay A, Crook T, Ozturk M, Luluq IG: Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res Commun 2002;299:839–846.
Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225–2234.
Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, Holbrook NJ: Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res 2002;62:3257–3263.
Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–987.
Adell G, Zhang H, Evertsson S, Sun XF, Stal OH, Nordenskjold BA: Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer 2001;91:1870–1875.
Adell G, Zhang H, Jansson A, et al: Decreased tumour cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2001;50:659–663.
Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R, Nordenskjold B: p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169–174.
Pfeifer D, Gao J, Adell G, Sun XF: Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:1143–1148.
Wallin A, Svanvik J, Adell G, Sun XF: Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:452–458.
Losi L, Ponti G, Gregorio CD, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP: Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006;202:663–670.
Jimenez-Anula J, Luque RJ, Gaforio JJ, Delgado M: Prognostic value of invasive growth pattern in sporadic colorectal cancer. Cir Esp 2005;77:337–342.
Meyer JS: Growth and cell kinetic measurements in human tumors. Pathol Annu 1981;16:53–81.
Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
Stephens BJ, Han H, Gokhale V, Von Hoff DD: PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005;4:653–661.
Reid TS, Terry KL, Casey PJ, Beese LS: Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004;343:417–433.
Fiordalisi JJ, Keller PJ, Cox AD: PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006;66:3153–3161.
Gao J, Arbman G, Reader A, Sun XF: Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004;6:796–801.
Sun XF: p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002;8:165–170.
Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369–1373.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.